Skip to main content
Caplight Logo









OncoSenX

OncoSenX

Private
Seattle, WashingtonHealthcare & Life Scienceshttps://www.oncosenx.com/

Last Round

VC Round

Aug 5, 2021

Total Funding Raised

$5.5M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

OncoSenX is a biotechnology company that develops transient gene therapies designed to treat cancer. The company's therapy delivers a program that induces apoptosis in cancerous cells using a plasmid DNA delivered with a proteo-lipid vehicle that selectively kills cancerous cells based on their transcriptional activity.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

gene therapysolid tumor therapylipid nanoparticleLNPcancer gene therapyoncology therapeuticsnon-viral deliveryDNA plasmiddrug delivery systemtranscriptional targetingProteo-Lipid VehiclePLVpreclinical biotechnologyprogrammable therapeuticsapoptosis induction

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

OncoSenX Comparables

Compare OncoSenX with similar companies based on industry and business-model similarity.

OncoSenX comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Oisín Biotechnologies
79%
Entos Pharmaceuticals
76%
BreezeBio
68%

OncoSenX Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundAug 5, 2021
Series AApr 1, 2020
Pre SeedJul 8, 2019
SeedMar 14, 2019

Key People

Founding team and executive leadership

Matthew Scholz

Chief Executive Officer

Executive Team

Eric Garcia

Chief Operating Officer

Executive Team

OncoSenX Investors

Notable investors and investment history

OncoSenX investors
InvestorRounds
Helios CapitalVC Round
AltheaPre Seed
Methuselah FoundationVC Round, Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 33% MoM.

  • May 18, 2026

    Monthly visitors increased 105% MoM.

OncoSenX Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

OncoSenX Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about OncoSenX's valuation, stock price, and market status.

Firmographic Details

HeadquartersSeattle, Washington
Employee Range8
Year Founded2017
Last FundingAug 5, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?